The first quarter of the year saw biotech stock indices rise by 17–18%. Of $3.1 billion in total funding, seven companies raised $454.2 million via initial public offerings (IPOs), a record 34 follow-on deals totaling $2 billion were completed and private investments in public equity accounted for $584.6 million. More than $4 billion was raised from debt financings, of which $2.2 billion came from Gilead Sciences (Foster City, CA) to help fund its acquisition of Pharmasset (Princeton, NJ). Private biotechs raised $1.1 billion in 1Q12, versus $1 billion in 1Q11.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. Biotech equities heat up in 1Q12. Nat Biotechnol 30, 384 (2012). https://doi.org/10.1038/nbt.2211
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2211
